VIDEO: MCO-010 demonstrates vision improvements, safety in retinitis pigmentosa
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2025, Allen C. Ho, MD, discusses the growing promise of optogenetic therapy in treating patients with retinal disease.
Data from a randomized, multicenter, sham-controlled program investigating MCO-010 (Nanoscope Therapeutics) in 27 patients with retinitis pigmentosa demonstrated “significant improvements” in vision with low and high doses as well as a positive safety profile, according to Ho.
“We may have a mutation-agnostic approach for introducing light-sensitive engineered opsins into remaining retinal cells for patients with severe retinal degeneration,” he said.
Collapse
Ho AC. Optogenetic strategies for retinal disease 2025. Presented at: Retina 2025; Jan. 18-24, 2025; Koloa, Hawaii.
Read more about